Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 3
2008 1
2009 4
2010 5
2011 3
2012 9
2013 5
2014 4
2015 6
2016 7
2017 8
2018 10
2019 11
2020 8
2021 8
2022 10
2023 15
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Lecanemab: First Approval.
Hoy SM. Hoy SM. Drugs. 2023 Mar;83(4):359-365. doi: 10.1007/s40265-023-01851-2. Drugs. 2023. PMID: 36856953 Review.
Bexagliflozin: First Approval.
Hoy SM. Hoy SM. Drugs. 2023 Apr;83(5):447-453. doi: 10.1007/s40265-023-01848-x. Drugs. 2023. PMID: 36867399 Review.
Elacestrant: First Approval.
Hoy SM. Hoy SM. Drugs. 2023 Apr;83(6):555-561. doi: 10.1007/s40265-023-01861-0. Drugs. 2023. PMID: 37060385 Free PMC article. Review.
Deucravacitinib: First Approval.
Hoy SM. Hoy SM. Drugs. 2022 Nov;82(17):1671-1679. doi: 10.1007/s40265-022-01796-y. Drugs. 2022. PMID: 36401743 Free PMC article. Review.
Tezepelumab: First Approval.
Hoy SM. Hoy SM. Drugs. 2022 Mar;82(4):461-468. doi: 10.1007/s40265-022-01679-2. Drugs. 2022. PMID: 35184265 Review.
Patisiran: First Global Approval.
Hoy SM. Hoy SM. Drugs. 2018 Oct;78(15):1625-1631. doi: 10.1007/s40265-018-0983-6. Drugs. 2018. PMID: 30251172 Review.
Rozanolixizumab: First Approval.
Hoy SM. Hoy SM. Drugs. 2023 Sep;83(14):1341-1347. doi: 10.1007/s40265-023-01933-1. Drugs. 2023. PMID: 37656420 Free PMC article. Review.
Exagamglogene Autotemcel: First Approval.
Hoy SM. Hoy SM. Mol Diagn Ther. 2024 Mar;28(2):133-139. doi: 10.1007/s40291-024-00696-z. Epub 2024 Jan 17. Mol Diagn Ther. 2024. PMID: 38228954 Review.
Pozelimab: First Approval.
Hoy SM. Hoy SM. Drugs. 2023 Nov;83(16):1551-1557. doi: 10.1007/s40265-023-01955-9. Drugs. 2023. PMID: 37856038 Review.
122 results